US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

F/m Emerald Life Sciences Innovation ETF

45.97

+0.26860.59%

Post-market: 45.51-0.4564-0.99%16:15 EDT

Volume:2K

Turnover:106.96K

Market Cap:126.73M

PE:- -

High:46.65

Open:46.65

Low:45.51

Close:45.70

52wk High:48.78

52wk Low:27.68

Shares:2.76M

Float Shares:2.76M

Volume Ratio:0.85

T/O Rate:0.08%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Spyre Therapeutics Announces Grants of Inducement Awards

Oxford Biomedica trims 2026 outlook but leans on record client wins and growing pipeline

Ardelyx Says Q2 Product Revenue at Record High but Ibsrela Revenue Below Expectations

iRhythm Q2 Revenue Beats Estimates on Sustained Volume Demand, Lifts FY Guidance

Pulse Biosciences Q2 Net Loss Widens, Cash Position Strengthens

Travere Therapeutics, Inc. : Wedbush Raises Target Price to $75 from $61

THOMSON REUTERS

Regulatory Uncertainty Threatens Travere Therapeutics’ Cross-Border Deals and Partnerships

Circio’s circVec gene therapy platform secures oral slot at top European ESGCT conference

Spyre Therapeutics CEO Turtle Cameron Sells Common Shares Worth $1.42 Million

LivaNova PLC Lifts Guidance on Record Q2 Results

Takeda Wins First-in-Class U.S. Approval for Orexin Therapy in Narcolepsy Type 1

Travere Therapeutics to Present at Canaccord Genuity Growth Conference

Guardant Health Director Ian T. Clark Disposes of Common Shares Worth $2.25 Million

Akebia Q2 Revenue Falls on Lower Auryxia Sales

Sarepta Q2 Results Beat Expectations Despite Lower Sales Stemming from Elevidys Relabel, Unmet Roche Milestone

Nyxoah Q2 Revenue Surges on U.S. Growth, but Margins Drop

Mirum Pharmaceuticals Q2 Sales Rise, Lifts Outlook

LivaNova is Maintained at Buy by Needham

LivaNova PLC Reports Results for the Quarter Ended June 30 - Earnings Summary

Compass Pathways' Q2 Loss Widens on Commercial Readiness Activity Costs

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/LFSC/news?page=7"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LFSC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LFSC\",,,,,undefined,":{"symbol":"LFSC","market":"US","secType":"STK","nameCN":"F/m Emerald Life Sciences Innovation ETF","latestPrice":45.9664,"timestamp":1788379200000,"preClose":45.6978,"halted":0,"volume":2330,"hourTrading":{"tag":"盘后","latestPrice":45.51,"preClose":45.9664,"latestTime":"16:15 EDT","volume":10,"amount":459.664,"timestamp":1788380100276,"change":-0.4564,"changeRate":-0.009929,"amplitude":0},"delay":0,"changeRate":0.005877744661668598,"floatShares":2757035,"shares":2757035,"eps":0,"marketStatus":"Closed","change":0.2686,"latestTime":"09-02 16:00:00 EDT","open":46.65,"high":46.65,"low":45.51,"amount":106959,"amplitude":0.024946,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1788422400000},"marketStatusCode":5,"adr":0,"exchange":"NASDAQ","adjPreClose":45.6978,"sharesOutstanding":2657035,"nav":45.72,"aum":126051640.2,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":45.51,"preClose":45.9664,"latestTime":"16:15 EDT","volume":10,"amount":459.664,"timestamp":1788380100276,"change":-0.4564,"changeRate":-0.009929,"amplitude":0},"volumeRatio":0.854983},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LFSC\",,,,,undefined,":{"symbol":"LFSC","floatShares":2757035,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.854983,"shares":2757035,"dividePrice":0,"high":46.65,"amplitude":0.024946,"preClose":45.6978,"low":45.51,"week52Low":27.6794,"pbRate":"--","week52High":48.78,"institutionHeld":0,"latestPrice":45.9664,"eps":0,"divideRate":0,"volume":2330,"delay":0,"ttmEps":0,"open":46.65,"prevYearClose":36.6147,"prevWeekClose":45.9566,"prevMonthClose":45.79,"prevQuarterClose":45.2033,"fiveDayClose":47.5848,"twentyDayClose":47.4383,"sixtyDayClose":37.87},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LFSC\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LFSC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LFSC\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LFSC\",pageSize:20,pageCount:7,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2657626551","title":"Spyre Therapeutics Announces Grants of Inducement Awards","url":"https://stock-news.laohu8.com/highlight/detail?id=2657626551","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657626551?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:05","pubTimestamp":1786133100,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., Aug.  07, 2026  (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company committed to developing next-generation t","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/07/3341387/0/en/spyre-therapeutics-announces-grants-of-inducement-awards.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","LENZ","SYRE","BK4539","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657369495","title":"Oxford Biomedica trims 2026 outlook but leans on record client wins and growing pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2657369495","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657369495?lang=en_us&edition=fundamental","pubTime":"2026-08-07 14:11","pubTimestamp":1786083103,"startTime":"0","endTime":"0","summary":"An update from Oxford BioMedica ( ($GB:OXB) ) is now available. Oxford Biomedica, a specialist cell and gene therapy CDMO, reported around 9% reven...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/oxford-biomedica-trims-2026-outlook-but-leans-on-record-client-wins-and-growing-pipeline?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/oxford-biomedica-trims-2026-outlook-but-leans-on-record-client-wins-and-growing-pipeline?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4202","OXM","BK4585","HELX","CNCR","SYNB","LFSC","IBBQ","IDNA","WDNA","FBT","BK4588","IBB","JDOC","GNOM","TBXU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657663618","title":"Ardelyx Says Q2 Product Revenue at Record High but Ibsrela Revenue Below Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2657663618","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657663618?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:49","pubTimestamp":1786049392,"startTime":"0","endTime":"0","summary":"Ardelyx says Q2 product revenue at record high but IBSRELA revenue below expectationsOverviewU.S. biopharma firm's Q2 product revenue rose 31% yr/yr to record $118.1 mlnIBSRELA Q2 revenue grew 33% but","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4431I0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ARDX","TVTX","ZVRA","MIRM","LFSC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657756668","title":"iRhythm Q2 Revenue Beats Estimates on Sustained Volume Demand, Lifts FY Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2657756668","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657756668?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:38","pubTimestamp":1786048730,"startTime":"0","endTime":"0","summary":"iRhythm Q2 revenue beats estimates on sustained volume demand, lifts FY guidanceOverviewDigital health care firm's Q2 revenue rose 20% yr/yr, beating analyst expectationsAdjusted net income turned pos","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4431G3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU0006061336.USD","LU1854104046.USD","BK4504","LU0162691827.USD","LU1854103824.USD","LU0266013472.USD","IE00BFXG1179.USD","LU0511384066.AUD","LU1201861165.SGD","BK4563","BK4585","LU0130518102.USD","LU0289961442.SGD","LU2065169927.USD","LU1150488218.USD","LU0068578508.USD","LFSC","LU0433182093.SGD","LU1150488135.SGD","LU2065171402.SGD","LU0985489474.SGD","IRTC","BDX","LU0130103400.USD","LU2065170008.USD","LU1059921491.USD","LU2065171311.SGD","BK4082","LU0985320562.USD","LU1894683348.USD","LIVN","LU0878866978.SGD","LU0072461881.USD","LU1894683264.USD","LU0477156797.USD","LU1571399168.USD","LU0648000940.SGD","LU1489326972.SGD","IHI","LU0289739343.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657650423","title":"Pulse Biosciences Q2 Net Loss Widens, Cash Position Strengthens","url":"https://stock-news.laohu8.com/highlight/detail?id=2657650423","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657650423?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:21","pubTimestamp":1786047690,"startTime":"0","endTime":"0","summary":"Pulse Biosciences Q2 net loss widens, cash position strengthensOverviewBioelectric medicine company's Q2 2026 revenue grew sequentially during controlled commercial launchGAAP net loss for Q2 widened ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4431GQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","LU2065170008.USD","PRCT","LU2324357040.USD","LIVN","MYO","LFSC","LU2065169927.USD","LU2065171311.SGD","PLSE","LU2065171402.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657363939","title":"Travere Therapeutics, Inc. : Wedbush Raises Target Price to $75 from $61","url":"https://stock-news.laohu8.com/highlight/detail?id=2657363939","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657363939?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:10","pubTimestamp":1786018250,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nFWN4431LV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LFSC","BK4139","TVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657502347","title":"Regulatory Uncertainty Threatens Travere Therapeutics’ Cross-Border Deals and Partnerships","url":"https://stock-news.laohu8.com/highlight/detail?id=2657502347","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657502347?lang=en_us&edition=fundamental","pubTime":"2026-08-06 14:01","pubTimestamp":1785996100,"startTime":"0","endTime":"0","summary":"Travere Therapeutics, Inc. (TVTX) has disclosed a new risk, in the Corporate Activity and Growth category. Travere Therapeutics, Inc. faces growing...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/regulatory-uncertainty-threatens-travere-therapeutics-cross-border-deals-and-partnerships?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/regulatory-uncertainty-threatens-travere-therapeutics-cross-border-deals-and-partnerships?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4539","BK4139","LENZ","LFSC","FFTY","TVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657023575","title":"Circio’s circVec gene therapy platform secures oral slot at top European ESGCT conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2657023575","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657023575?lang=en_us&edition=fundamental","pubTime":"2026-08-06 13:45","pubTimestamp":1785995139,"startTime":"0","endTime":"0","summary":"Targovax ASA ( ($GB:0RIS) ) has shared an announcement. Circio Holding ASA, a biotechnology company specializing in circular RNA expression systems...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/circios-circvec-gene-therapy-platform-secures-oral-slot-at-top-european-esgct-conference?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/circios-circvec-gene-therapy-platform-secures-oral-slot-at-top-european-esgct-conference?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LNGR","FBT","RSPH","DARP","XT","IE0009354923.USD","TBXU","RNA","SYNB","BK4505","LFSC","BK4588","FWD","BBP","EPV","GNOM","IEIH","JDOC","IBBQ","FHLC","RDMX","BK4585","AGNG","CNCR","IBB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657508141","title":"Spyre Therapeutics CEO Turtle Cameron Sells Common Shares Worth $1.42 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657508141","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657508141?lang=en_us&edition=fundamental","pubTime":"2026-08-06 09:32","pubTimestamp":1785979921,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics CEO Turtle Cameron sells common shares worth $1.42 millionSpyre Therapeutics CEO Turtle Cameron sold 15,000 common shares on Aug. 3 at weighted-average prices of $93.97 to $97.46.Ca","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDLnGFtZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Spyre Therapeutics CEO Turtle Cameron Sells Common Shares Worth $1.42 Million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFSC","BK4139","SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657570531","title":"LivaNova PLC Lifts Guidance on Record Q2 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2657570531","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657570531?lang=en_us&edition=fundamental","pubTime":"2026-08-06 08:26","pubTimestamp":1785975964,"startTime":"0","endTime":"0","summary":"LivaNova PLC (($LIVN)) has held its Q2 earnings call. Read on for the main highlights of the call. LivaNova PLC’s latest earnings call painted an u...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/livanova-plc-lifts-guidance-on-record-q2-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/livanova-plc-lifts-guidance-on-record-q2-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2065170008.USD","LFSC","BK4082","LU2065171311.SGD","LU2065171402.SGD","LIVN","RGLO","LU2065169927.USD","JOYT","GXDW","PMDE","VGFPF","FEBU","VOTE","DECU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657572786","title":"Takeda Wins First-in-Class U.S. Approval for Orexin Therapy in Narcolepsy Type 1","url":"https://stock-news.laohu8.com/highlight/detail?id=2657572786","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657572786?lang=en_us&edition=fundamental","pubTime":"2026-08-06 07:25","pubTimestamp":1785972320,"startTime":"0","endTime":"0","summary":"The latest update is out from Takeda Pharmaceutical Co ( ($JP:4502) ). Takeda has secured U.S. FDA approval for ORZEYFUL, an oral orexin receptor 2...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/takeda-wins-first-in-class-u-s-approval-for-orexin-therapy-in-narcolepsy-type-1?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/takeda-wins-first-in-class-u-s-approval-for-orexin-therapy-in-narcolepsy-type-1?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MRNX","MRNY","IBB","IYH","BK4585","TECB","PINK","IDNA","SYNB","RSPH","TBXU","GDOC","MEDI","LABU","BK4588","PSCH","BMED","GNMX","LFSC","XLVX","FRTY","BBP","IEIH","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657757137","title":"Travere Therapeutics to Present at Canaccord Genuity Growth Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2657757137","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657757137?lang=en_us&edition=fundamental","pubTime":"2026-08-06 05:48","pubTimestamp":1785966534,"startTime":"0","endTime":"0","summary":"Travere Therapeutics to present at Canaccord Genuity Growth ConferenceTravere Therapeutics management will present at Canaccord Genuity’s 46th Annual Growth Conference on Aug. 11, 2026 at 3 p.m. ET.Ex","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nNDL9MT5yQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2360032135.SGD","BK4559","LU0098860793.USD","LU1074936037.SGD","LU1791807156.HKD","LU1267930227.SGD","LU0128525689.USD","LU0162691827.USD","LU0310800965.SGD","LU1201861249.SGD","LU0477156953.USD","LU2125154935.USD","LU1244550577.SGD","LU1366192091.USD","LU0052756011.USD","IYF","LU1506573853.SGD","BK4585","LU1668664300.SGD","LU1244550221.USD","IE00BSNM7G36.USD","LU2456880835.USD","LU1162221912.USD","LU0130517989.USD","LFSC","LU0170899867.USD","TFNS","LU2417539215.USD","BK4588","BK4566","LU0320765646.SGD","BK4504","LU0130102774.USD","BK4207","LU2462157665.USD","LU1244550494.USD","BK4534","LU0106831901.USD","LU2125154778.USD","TVTX","LU0314106906.USD","LU0203347892.USD","LU0980610538.SGD","FTXO","LU2236285917.USD","BK4139","LU0203345920.USD","LU0648001328.SGD","LU0072461881.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657726576","title":"Guardant Health Director Ian T. Clark Disposes of Common Shares Worth $2.25 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657726576","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657726576?lang=en_us&edition=fundamental","pubTime":"2026-08-06 05:11","pubTimestamp":1785964302,"startTime":"0","endTime":"0","summary":"Guardant Health director Ian T. Clark disposes of common shares worth $2.25 millionGuardant Health director Ian T. Clark reported option exercises on Aug. 4, 2026, acquiring 9,088 common shares at USD","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nNDL7mNXxZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Guardant Health Director Ian T. Clark Disposes of Common Shares Worth $2.25 Million","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4551","GNOM","PTH","FFOX","HELX","BK4196","BK4588","LU0109394709.USD","GDOC","GH","GNMX","LFSC","BK4585","LU0889565916.HKD","BK4535","EKG","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657655575","title":"Akebia Q2 Revenue Falls on Lower Auryxia Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2657655575","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657655575?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:45","pubTimestamp":1785962756,"startTime":"0","endTime":"0","summary":"Akebia Q2 revenue falls on lower Auryxia salesOverviewU.S. kidney disease drugmaker's Q2 revenue fell yr/yr on lower Auryxia salesQ2 net loss and loss per share both beat analyst expectationsVafseo Q2","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL1N4421F9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","AKBA","TVTX","BK4139","LFSC","BK4196","BK4559","BK4585","DVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657957897","title":"Sarepta Q2 Results Beat Expectations Despite Lower Sales Stemming from Elevidys Relabel, Unmet Roche Milestone","url":"https://stock-news.laohu8.com/highlight/detail?id=2657957897","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657957897?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:22","pubTimestamp":1785961340,"startTime":"0","endTime":"0","summary":"Sarepta Q2 results beat expectations despite lower sales stemming from Elevidys relabel, unmet Roche milestoneOverviewUS rare disease drugmaker's Q2 revenue fell 34% yr/yr but beat analyst expectation","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL1N4421ER:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE0002141913.USD","BK4547","SRPT","IE00B2B36J28.USD","SRPU","TVTX","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","IE0009355771.USD","LFSC","BCRX","BK4139","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657578847","title":"Nyxoah Q2 Revenue Surges on U.S. Growth, but Margins Drop","url":"https://stock-news.laohu8.com/highlight/detail?id=2657578847","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657578847?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:16","pubTimestamp":1785961004,"startTime":"0","endTime":"0","summary":"Nyxoah Q2 revenue surges on U.S. growth, but margins dropOverviewBelgium medical device maker's Q2 revenue rose sharply yr/yr on U.S. commercializationGross margin for Q2 declined to 60% from 63% due ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL1N4421BK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","BK4588","LU2065171311.SGD","LU1261432733.SGD","BK4082","LU1084165304.USD","BK4167","INSP","LU0728928796.USD","LFSC","LU2065169927.USD","LU2065731478.USD","BK4551","LU2065170008.USD","LU1119994496.HKD","LU2324357040.USD","BK4585","PODD","LU2065171402.SGD","LIVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657520974","title":"Mirum Pharmaceuticals Q2 Sales Rise, Lifts Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2657520974","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657520974?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:12","pubTimestamp":1785960723,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals Q2 sales rise, lifts outlookOverviewRare disease drugmaker's Q2 net product sales rose 38% yr/yr to $176 mlnCompany raised 2026 net product sales guidance to $680 mln-$700 mlnQ2 ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL1N4421AC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0057025933.USD","LU0124676726.USD","LU0154245673.USD","BK4533","LU0689626769.HKD","LU2065170008.USD","CMI","BK4567","BK4139","LU2065171311.SGD","MADE","LU0154245756.USD","LU0203345920.USD","BK4149","LU0069063385.USD","LU0511384066.AUD","LU2065169927.USD","LU0203347892.USD","LU2463526074.USD","ACAD","LU0289961442.SGD","BK4585","LFSC","LU0472753341.HKD","LU2065171402.SGD","BK4588","MIRM","LU0289739343.SGD","TVTX","IE000M9KFDE8.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657521011","title":"LivaNova is Maintained at Buy by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2657521011","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657521011?lang=en_us&edition=fundamental","pubTime":"2026-08-06 01:53","pubTimestamp":1785952380,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LIVN/analyst-ratings","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFSC","LU2065171311.SGD","BK4082","LIVN","LU2065171402.SGD","LU2065169927.USD","LU2065170008.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657540505","title":"LivaNova PLC Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657540505","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657540505?lang=en_us&edition=fundamental","pubTime":"2026-08-05 21:32","pubTimestamp":1785936720,"startTime":"0","endTime":"0","summary":"LivaNova PLC reports results for the quarter ended June 30 - Earnings SummaryLivaNova PLCLIVN.OQreported quarterly adjusted earnings of $1.26 per share for the quarter ended June 30, higher than the s","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL8N44223Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065171311.SGD","LU2065169927.USD","LFSC","LU2065171402.SGD","LIVN","BK4082","LU2065170008.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657545831","title":"Compass Pathways' Q2 Loss Widens on Commercial Readiness Activity Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2657545831","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657545831?lang=en_us&edition=fundamental","pubTime":"2026-08-05 18:45","pubTimestamp":1785926714,"startTime":"0","endTime":"0","summary":"Compass Pathways' Q2 loss widens on commercial readiness activity costsOverviewUK mental health biotech's Q2 operating income missed analyst estimatesNet loss widened yr/yr, mainly due to non-cash war","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL1N4420FQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2279689827.SGD","LFSC","LU0096364046.USD","ACAD","CMPS","LU2089284900.SGD","LU2539964713.USD","LU1670710588.SGD","FTXH","LU1273509221.SGD","LU1585245621.USD","LU1989772923.USD","SG9999013999.USD","LU2237443978.SGD","LU0321505868.SGD","LU0432979614.USD","PSIL","SG9999001176.USD","03165","LU1983299246.USD","LU1046234339.USD","LU2125154935.USD","LU1153585028.USD","LU1291159041.SGD","LU0985481810.HKD","LU0310799852.SGD","LU2065171311.SGD","LU0496365809.HKD","LIVN","LU0575583348.USD","LU2596442595.SGD","LU0526926950.USD","IHE","LU0203345920.USD","BMY","LU0266013472.USD","BK4007","AZN.UK","LU0997586432.USD","LU1196032939.SGD","LU1057294990.SGD","LU0757432116.USD","LU2065170008.USD","LU1880407215.USD","LU0306807586.USD","LU1863844749.USD","SGXZ57979304.SGD","LU1718418525.SGD","LU0211326839.USD","LU1481600234.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":7,"totalSize":200,"code":"91000000","status":"200"}]}}